Beurs gesloten -
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
15,13 USD | +0,87% | +5,29% | +121,85% |
Vakgebied
Aantal werknemers: 100
Verkoop per activiteit
USD in miljoen | 2022 | Gewicht | 2023 | Gewicht | Delta |
---|---|---|---|---|---|
Novel Antibody-based Therapeutic Products
100,0
%
| 49 | 100,0 % | 84 | 100,0 % | +71,15% |
Verkoop per regio
USD in miljoen | 2022 | Gewicht | 2023 | Gewicht | Delta |
---|---|---|---|---|---|
United States
80,4
%
| 46 | 93,9 % | 68 | 80,4 % | +46,60% |
Other Countries
19,6
%
| 3 | 6,1 % | 17 | 19,6 % | +448,70% |
Managers
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Thomas Gad
FOU | Founder | 54 | 01-04-15 |
Michael Rossi
CEO | Chief Executive Officer | 53 | 06/11 |
Bo Kruse
DFI | Director of Finance/CFO | 52 | 01-06-16 |
Vignesh Rajah
CTO | Chief Tech/Sci/R&D Officer | 59 | 01-06-20 |
Joris Wilms
COO | Chief Operating Officer | 50 | 01-11-17 |
Chief Tech/Sci/R&D Officer | 73 | 01-01-16 | |
Sue Smith
PRN | Corporate Officer/Principal | 54 | - |
Besturend
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
David Gill
BRD | Director/Board Member | 69 | 01-12-17 |
Director/Board Member | 54 | 01-09-15 | |
James Healy
CHM | Chairman | 58 | 01-11-17 |
Ashutosh Tyagi
BRD | Director/Board Member | 47 | 01-11-17 |
Bo Kruse
DFI | Director of Finance/CFO | 52 | 01-06-16 |
Gérard Ber
BRD | Director/Board Member | 66 | 11-12-18 |
Michael Rossi
CEO | Chief Executive Officer | 53 | 06/11 |
Thomas Gad
FOU | Founder | 54 | 01-04-15 |
Laura Hamill
BRD | Director/Board Member | 60 | 01-04-20 |
Aandelenklasse
Stemming | Aantal | Vrij verhandelbaar | Bedrijfseigen aandelen | Drijvend Totaal | |
---|---|---|---|---|---|
Aandeel A | 1 | 43 777 105 | 37 409 819 ( 85,46 %) | 0 | 85,46 % |
Bedrijfsgegevens
Sector
Verkoop per regio
Herzieningen van WPA
Vaira. 1 jan. | Kapi. | |
---|---|---|
+121,85% | 662 mln. | |
-3,10% | 102 mld. | |
+2,11% | 96,37 mld. | |
-1,80% | 21,37 mld. | |
-17,75% | 20,92 mld. | |
-6,91% | 18,64 mld. | |
-42,00% | 16,4 mld. | |
-28,19% | 13,53 mld. | |
+19,90% | 10,85 mld. | |
-23,23% | 8,4 mld. |
- Beurs
- Aandelen
- Koers YMAB
- Onderneming Y-mAbs Therapeutics, Inc.